Bio­gen scores a pri­or­i­ty re­view for its Alzheimer's drug ad­u­canum­ab, mov­ing one gi­ant leap for­ward in its con­tro­ver­sial quest

Bio­gen scored a big win at the FDA to­day as reg­u­la­tors ac­cept­ed their ap­pli­ca­tion for the con­tro­ver­sial Alzheimer’s drug ad­u­canum­ab and gave it a pri­or­i­ty re­view.

The PDU­FA date is March 7, 2021.

Sig­nif­i­cant­ly, Bio­gen says it did not use its pri­or­i­ty re­view vouch­er to win spe­cial treat­ment at the FDA. The agency hand­ed that out gratis.

That’s the ide­al sce­nario Bio­gen was look­ing for as dis­ap­point­ed an­a­lysts won­dered aloud about the de­layed ap­pli­ca­tion ear­li­er in the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER